EUVIMEDEUVIMED entdecken
Open Access

Development of Dual Aurora‐A and Aurora‐B Degrading PROTACs for MYCN ‐Amplified Neuroblastoma

Sydney E Nelson, James R Tucker, Madelen G Prado, Lillian C Tierney, Sarah L Quigley, Andrew T Lumpkin, Cayden J Dodd, Viola Hasko, Savannah L Howie, Aastha, Britton K Ody, Jun Yin und 2 weitere

ChemMedChem · 2025

DOI: 10.1002/cmdc.202400703 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2025. Verfasst von Sydney E Nelson und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biochemistry, Berry College, Mount Berry, GA 30149 (USA). Hauptthemen laut MEDLINE: Neuroblastoma, Aurora Kinase A, Aurora Kinase B, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In neuroblastoma, MYCN amplification is associated with survival rates of

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaAurora Kinase AAurora Kinase BAntineoplastic AgentsProtein Kinase InhibitorsHumansProteolysisCell Line, TumorMolecular StructureN-Myc Proto-Oncogene ProteinDrug Screening Assays, AntitumorStructure-Activity RelationshipDose-Response Relationship, DrugCell ProliferationProteolysis Targeting Chimera

Stichwörter der Autor:innen

Aurora-AAurora-BN-MycPROTACneuroblastoma

Substanzen

Aurora Kinase AAurora Kinase BAURKB protein, humanAntineoplastic AgentsProtein Kinase InhibitorsN-Myc Proto-Oncogene ProteinAURKA protein, humanMYCN protein, humanProteolysis Targeting Chimera

Autor:innen und Institutionen

  • Department of Chemistry and Biochemistry, Berry College, Mount Berry, GA 30149 (USA).
  • Department of Chemistry, Washington University in St. Louis, St. Louis, MO 63130 (USA).
  • Department of Chemistry, Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA 30303 (USA).

Förderung

  • NIGMS NIH HHS
  • National Institutes of Health

Zitieren

APA

Nelson, S. E., Tucker, J. R., Prado, M. G., Tierney, L. C., Quigley, S. L., Lumpkin, A. T., Dodd, C. J., Hasko, V., Howie, S. L., Aastha, Ody, B. K., Yin, J., Heemstra, J. M., & Turlington, M. (2025). Development of Dual Aurora‐A and Aurora‐B Degrading PROTACs for MYCN ‐Amplified Neuroblastoma. ChemMedChem. https://doi.org/10.1002/cmdc.202400703

Vancouver

Nelson SE, Tucker JR, Prado MG, Tierney LC, Quigley SL, Lumpkin AT, et al. Development of Dual Aurora‐A and Aurora‐B Degrading PROTACs for MYCN ‐Amplified Neuroblastoma. ChemMedChem. 2025. doi:10.1002/cmdc.202400703

BibTeX
@article{Nelson2025,
  author = {Nelson, Sydney E and Tucker, James R and Prado, Madelen G and Tierney, Lillian C and Quigley, Sarah L and Lumpkin, Andrew T and Dodd, Cayden J and Hasko, Viola and Howie, Savannah L and Aastha and Ody, Britton K and Yin, Jun and Heemstra, Jennifer M and Turlington, Mark},
  title = {Development of Dual Aurora‐A and Aurora‐B Degrading PROTACs for MYCN ‐Amplified Neuroblastoma},
  journal = {ChemMedChem},
  year = {2025},
  doi = {10.1002/cmdc.202400703}
}
Kostenlos starten →